Outcome of kidney transplantation using organs from executed prisoners: Is it justified beyond the ethical issue?

Journal of the Chinese Medical Association

Volumn 70, Issue 5, 2007, Pages 193-199

  Shu, Kuo Hsiung ^a,b   Wu, Ming Ju ^a,b   Chen, Cheng Hsu ^a   Cheng, Chi Hung ^a,b   Lian, Jong Da ^b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Executed prisoner; Kidney transplantation; Organ donation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHINA; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; ORGAN DONOR; OUTCOMES RESEARCH; POSTOPERATIVE COMPLICATION; PRISONER; REPEATED DRUG DOSE; SURVIVAL RATE;

EID: 34250641103     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70357-0     Document Type: Article

References (22)

1. US Renal Data System Annual Report, 2005. International comparison 2005.
2. Briggs JD. The use of organs from executed prisoners in China. Nephrol Dial Transplant 1996;11:238-40.
3. Cameron JS, Hoffenberg R. The ethics of organ transplantation reconsidered: paid organ donation and the use of executed prisoners as donors. Kidney Int 1999;55:724-32.
4. Miller RB. Ethics of paid organ donation and the use of executed prisoners as donors: a dialectic with professors Cameron and Hoffenberg. Kidney Int 1999;55:733-7.
5. Cheng IK, Lai KN, Au TC, Chan PS, Poon GP, Chan YT. Comparison of the mortality and morbidity rates between proper and unconventional renal transplantation using organs from executed prisoners. Transplant Proc 1991;23:2533-6.
6. Kennedy SE, Shen Y, Charlesworth JA, Mackie JD, Mahony JD, Kelly JJ, Pussell BA. Outcome of overseas commercial kidney transplantation: an Australian perspective. Med J Aust 2005; 182:224-7.
7. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H. Cardiovascular risk in chronic renal disease and transplantation prevention and management. Expert Opin Pharmacother 2005;6: 929-43.
8. Opelz G, for the Collaborative Transplant Study. HLA matching in Asian recipients of kidney grafts from unrelated living or cadaveric donors. Hum Immunol 2000;61:115-9.
9. Morris PJ, Johnson RJ, Fuggle SV, Belger MA, Briggs JD. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA). Lancet 1999;354:1147-52.
10. Su X, Zenios SA, Chakkera H, Milford EL, Chertow GM. Diminishing significance of HLA matching in kidney transplantation. Am J Transplant 2004;4:1501-8.
11. Gill JS, Tonelli M, Johnson N, Pereira BJ. Why do preemptive kidney transplant recipients have an allograft survival advantage? Transplantation 2004;78:873-9.
12. Mange KC, Weir MR. Preemptive renal transplantation: why not? Am J Transplant 2003;3:1336-40.
13. Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, Cheung AK. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant 2005;20:167-75.
14. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Br Med J 2005;331:810.
15. Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005;80(Suppl): 191-200.
16. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12.
17. Sung JL. Hepatitis B virus infection and its sequelae in Taiwan. Proc Natl Sci Council ROC 1981;5:385-99.
18. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800.
19. Chan CY, Lee SD, Lo KJ. Legend of hepatitis B vaccination: the Taiwan experience. J Gastroenterol Hepatol 2004;19:121-6.
20. Lee WC, Wu MJ, Cheng CH, Chen CH, Shu KH, Lian JD. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001;38: 1074-81.
21. Shu KH, Lan JL, Wu MJ, Cheng CH, Chen CH, Lee WC, Chang HR, et al. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004;77:1894-6.
22. Yang TC, Shu KH, Cheng CH, Wu MJ, Lian JD. Malignancy following renal transplantation. J Chin Med Assoc 1998;61: 281-8.